PK and PD analyses
PD
The PK profile of the anti-PD-1 and anti-CTLA-4 components of QL1706 were characterized separately by using two different anti-idiotypic antibodies that are specific to each component. The exposure of both anti-CTLA-4 and anti-PD-1 increased as the dose increased following single and multiple dosing (Fig. Mean (± standard deviation) plasma concentrations of anti-CTLA-4 (For PD analysis, the level of PD-1 target coverage was assessed by a receptor occupancy assay on circulating CD3